Moores Scientific Retreat Less Than a Month Away!
|
The Moores Scientific Retreat will take place Wednesday, September 4, 2024 from 7:30 a.m. to 5:30 p.m. at the Scripps Seaside Forum. Karandeep Singh, MD is the keynote speaker, and Moores Director Diane Simeone, MD will deliver a special presentation.
|
Moores Members Receive the Lustgarten Foundation Clinical Accelerator Initiative (CAI) Grant
|
Moores Members Andrew Lowy, MD and Shweta Joshi, PhD secured a Lustgarten CAI grant, which speeds the translation of basic research in the clinic by supporting novel, science-driven clinical trials, to advance their study of pancreatic cancer therapies.
|
California HPV Vaccine Week August 4–10, 2024
|
The CDC maintains that 85% of the population will contract HPV over the lifespan. During California HPV Vaccine Week, UC San Diego Health physicians and community partners will demonstrate the importance of vaccination in the fight against HPV and cervical cancer.
|
|
|
Yu-Wei Chen, MD, MS Awarded Robert A. Winn Diversity in Clinical Trials, Career Development Award
|
Moores Member Yu-Wei Chen has received a Robert A. Winn Career Development Award, which will support his efforts to improve patient outcomes and expand representation in clinical studies. Kudos to not only Dr. Chen, but also the Moores Pre Award and Grant Development Team for their support of Dr. Chen’s winning proposal.
|
Precision Oncology via Artificial Intelligence (AI) on Cancer Biopsies
|
Moores Members Ludmil Alexandrov, PhD, Erik Bergstrom, PhD, and Scott Lipmann, MD have identified new AI tools that can spot important genetic alterations directly from tumor biopsy slides, which will save time and money in cancer treatment.
|
|
|
August 7, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
August 9, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
August 21, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
August 27, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
September 26, 2024 | 9:00 a.m. to 3:30 p.m.
Moores Goldberg Auditorium and Comer Commons
|
|
|
Moores Member Highlighted in American Society of Hematology (ASH) Press Release about Mentorship
|
Moores Member Soo Park, MD features in an ASH press release regarding a study she will publish, which reveals that through completing a classical hematology mentorship program, mentees gained stronger professional identity and confidence in their career paths. A new partner program will leverage these findings in the fall.
|
Event Recap: Expanding Immunotherapy Efficacy by Understanding Mechanisms of Response Versus Resistance
|
On July 11, 2024, Moores welcomed Thomas F. Gajewski MD, PhD, who presented “Expanding Immunotherapy Efficacy by Understanding Mechanisms of Response Versus Resistance.” Co-hosted by Diane Simeone, MD, and J. Silvio Gutkind, PhD, the presentation addressed the mechanisms of checkpoint blockades, their limitations, and the ability to leverage this knowledge to propel advancements in cancer care.
|
Learning Health Systems Science Symposium
|
Thursday, August 15, 2024 | 1:00 p.m. to 5:00 p.m.
Medical Education and Telemedicine Auditorium, UC San Diego
In this inaugural symposium, attendees will learn how UC San Diego Health operates as a learning health system by engaging patients at various stages of care delivery, integrating team-based care and technology to serve patients at the right time and place, and providing opportunities for embedded scientists to contribute to the transformation of healthcare delivery through continuous learning and evidence-based practices.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
|
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for the RNA Modifications Driving Oncogenesis (RNAMoDO) initiative, which promotes fundamental studies in the emerging area of RNA modifications that underlie the oncogenic process, by addressing the central role of RNA modifications in translational reprogramming of cancer cells. This new initiative will comprise up to five U01 grants, which will be supported by this NOFO.
Submission Deadline: November 04, 2024
LOI Deadline: October 05, 2024
|
NCI R50 Research Specialist Awards
|
These awards encourage the development of stable research career opportunities for exceptional scientists who seek to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.
Laboratory-based Scientist Award (R50 Clinical Trial Not Allowed)
Non-tenure track scientists (e.g., researchers within a research program) are vital to sustaining the biomedical research enterprise. Exceptional scientists who seek to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, are encouraged to submit proposals.
LOI Deadline: October 1, 2024
Submission Deadline: November 1, 2024
|
Core-based Scientist Award (R50 Clinical Trial Not Allowed)
Project scientists (e.g., researchers within a core and/or shared resource, providing central scientific support) are vital to sustaining the biomedical research enterprise. This award provides salary support and sufficient autonomy so that these scientists are not solely dependent on NCI grants held by PIs for career continuity.
LOI Deadline: October 1, 2024
Submission Deadline: November 1, 2024
|
|
|
| Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults
|
The New England Journal of Medicine
|
Matthew J. Wieduwilt, MD, PhD (Hematologic Malignancies) and Dimitrios Tzachanis, MD, PhD (Hematologic Malignancies)
|
|
|
| Dietary acculturation is associated with altered gut microbiome, circulating metabolites, and cardiovascular disease risk in U.S. Hispanics and Latinos: Results from HCHS/SOL
|
American Heart Association: Circulation
|
Rob Knight, PhD (Structural and Functional Genomics)
|
|
|
|
Mutation in bruton tyrosine kinase (BTK) A428D confers resistance to BTK-degrader therapy in chronic lymphocytic leukemia
|
Michael Y. Choi, MD (Hematologic Malignancies), Huan-You Wang, MD, PhD (Hematologic Malignancies), and Thomas J. Kipps, MD, PhD (Hematologic Malignancies)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
EA8184: A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
|
PI: Aditya Bagrodia, MD, FACS
NCT: NCT04597359
|
|
|
|
